From junk into one with huge potential.
Probably a triple on FDA approval and a continued run higher.
There's little risk.
The international market is larger than the US.
Revenues will be rocketing even if FDA approval were not to be received.
He sold Neuvax to GALE for $7 million.
If this were the $billion per year blockbuster that the DreamTeam, dopeindenver and ourpoliticianssucks want you to believe it is, then why was it sold for only $7 million and no big pharma were interested.
You don't think Apthera was shopped to the highest bidder?
According to the founder "we found a subset of women who had not recurred, these were women with low and intermediate levels of HER2 expression. This observation was not obvious and thus we submitted patents on this very unusual observation, and the claims of this patent were just granted."
So, Apthera had a drug for a cherry picked subgroup with a patent limited to that subgroup, The general Neuvax patent expires in 2015. It's surprising that anyone would buy this drug and spend money developing it in trials that are sure to fail. But Apthera found a sucker. Perhaps Ahn just wanted a low priced drug that he could pump to gullible saps and didn't care that it will fail. He could have the DreamTeam pump the "science" (how blatantly ludicrous is that?) of a failed drug based on data mining,
Hit a nerve? Your PUMP & DUMP scam was exposed? So sorry!
HUGE LOSSES + HUGE DEBT = BANKRUPTCY
It should be sub $1.00 ...... looks like it's heading there ....... the P & D scammers wanted to unload some shares first.
I hope you did not get conned into this Pump & Dump scam and are still holding the junk.
AMRN was PUMPED on every board.
The DUMP will produce an equally dramatic plunge.
$3.33 to $2.85 is just the start.
It's an excellent time to sell.
Pfizer is "data mining" to improve the design of future trials. That means it is looking at the number of patients enrolled in each arm, it is looking at the severity of the illness in patients, it is looking at the length of trials.....
Pfizer is not rerunning failed trials with cherry picked patients. They are culling through data to try to improve future trials, perhaps how to collect the data more efficiently, logistics of the centers...........
Data mining to run another trial in a cherry picked subgroup is as close to a scam as you can get.